Galway, Ireland-based Aerogen’s proprietary vibrating mesh aerosol drug delivery technology will be used to deliver CanSinoBio’s recombinant novel coronavirus vaccine — Convidecia — under the development and commercial supply partnership. Commercial terms for the partnership were not disclosed.
Get the full story at our sister site, Drug Delivery Business News.
(Image from the CDC)
Chinese pharmaceutical company CanSino Biologics‘ COVID-19 vaccine candidate has received a patent from the Chinese government — the first such patent granted in the country.
Chinese state media outlet People’s Daily reported Sunday that the country’s National Intellectual Property Administration granted the patent for Ad5-nCoV, which uses a weakened human common cold virus to deliver genetic material that codes for the SARS-CoV-2 spike protein to the cells. These cells then produce the spike protein, and travel to the lymph nodes where the immune system creates antibodies that will recognize that spike protein and fight off the coronavirus, according to research published in The Lancet in July.
Get the full story on our sister site, MassDevice.
(Image from the CDC)
Chinese pharmaceutical company CanSino Biologics‘ COVID-19 vaccine candidate has received a patent from the Chinese government — the first such patent granted in the country.
Chinese state media outlet People’s Daily reported Sunday that the country’s National Intellectual Property Administration granted the patent for Ad5-nCoV, which uses a weakened human common cold virus to deliver genetic material that codes for the SARS-CoV-2 spike protein to the cells. These cells then produce the spike protein, and travel to the lymph nodes where the immune system creates antibodies that will recognize that spike protein and fight off the coronavirus, according to research published in The Lancet in July.
The phase 2 study reported in The Lancet involved 508 people in Wuhan, China, and found that the vaccine is safe and induces an immune response. A phase 3 trial, now bein…